Aspergillosis medical therapy

Jump to navigation Jump to search

Aspergillosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aspergillosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Aspergillosis medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aspergillosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aspergillosis medical therapy

CDC on Aspergillosis medical therapy

Aspergillosis medical therapy in the news

Blogs on Aspergillosis medical therapy

Aspergillosis

Risk calculators and risk factors for Aspergillosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Medical Therapy

Pharmacotherapy

  • A fungus ball is usually not treated (with antifungal medicines) unless there is bleeding into the lung tissue. In that case, surgery is needed.
  • Invasive aspergillosis is treated with several weeks of an antifungal drug called voriconazole. It can be given both oral and intravenous route. Amphotericin B, echinocandins, or itraconazole can also be used. Endocarditis caused by Aspergillus is treated by surgically removing the infected heart valves. Long-term antifungal therapy is also needed. [1]
  • Allergic aspergillosis: Antifungal drugs alone do not help people with allergic aspergillosis. Allergic aspergillosis is treated with drugs that suppress the immune system (immunosuppressive drugs) -- most often oral prednisone.

The drugs amphotericin B, caspofungin, flucytosine, itraconazole, voriconazole are used to treat this fungal infection.[2]

Characteristics of the Patient Possible Pathogens Preferred Treatment Alternative Treatment
Patient with a hematologic

malignancy

Aspergillus spp Voriconazole

Loading dose:6 mg/kg IV/ PO Q12H times two doses,

then 4 mg/kg IV/ PO Q12H

Ambisome:

5 mg/kg IV Q24H

Antimicrobial Regimen

  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • 2. Invasive sinus aspergillosis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • 3. Tracheobronchial aspergillosis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • 4. Chronic necrotizing pulmonary aspergillosis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • 5. Aspergillosis of the CNS
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: There are drug interactions with anticonvulsant therapy.
  • 6. Aspergillus infections of the heart (endocarditis, pericarditis, and myocarditis)
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: endocardial lesions generally require surgical treatment. Aspergillus pericarditis usually requires pericardiectomy.
  • 7. Aspergillus osteomyelitis and septic arthritis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: Surgical resection of devitalized bone and cartilage is important for curative intent.
  • 8. Aspergillus infections of the eye (endophthalmitis and keratitis)
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: Topical therapy is indicated for keratitis, ophthalmologic intervention and management is recommended for all forms of ocular infection. Systemic therapy may be beneficial when treating aspergillus endophthalmitis.
  • 9. Cutaneous aspergillosis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: Surgical resection is indicated when feasible.
  • 10. Aspergillus peritonitis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • 11. Prophylaxis against invasive aspergillosis
  • 12. Aspergilloma
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen: Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • 13. Chronic cavitary pulmonary aspergillosis
  • Preferred regimen: Voriconazole 6 mg/kg IV q12h single dose, THEN 4 mg/kg IV q12h or PO 200 mg q12h
  • Alternative regimen (1): Liposomal Amphotericin B (L-AMB) 3–5 mg/kg/day IV qd
  • Alternative regimen (2): Amphotericin B lipid complex (ABLC) 5 mg/ kg/day IV qd
  • Alternative regimen (3): Caspofungin 70 mg IV single dose THEN 50 mg/day IV qd
  • Alternative regimen (4): Posaconazole 200 mg PO qid if patient is critical, then 400 mg PO bid after stabilization of the disease.
  • Alternative regimen (5): Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (6): Micafungin 100–150 mg/day PO qd[4][3]
  • Note: Micafungin has been evaluated as salvage therapy for invasive aspergillosis but remains investigational for this indication, and the dosage has not been established.
  • Note: long-term therapy might be needed.
  • 14. Allergic bronchopulmonary Itraconazole aspergillosis
  • Preferred regimen: Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Alternative regimen (1): Voriconazole PO 200 mg bid
  • Alternative regimen (2): Posaconazole PO 400 mg bid
  • Note: Corticosteroids are a cornerstone of the therapy.
  • 15. Allergic aspergillus sinusitis
  • Preferred regimen: None or Itraconazole dosage depends upon formulation - 600 mg/day PO for 3 days, THEN 400 mg/day PO OR 200 mg q12h IV for 2 days, THEN 200 mg IV qd
  • Note: Few data available for other agents.
  • 16. Relative indications for surgical treatment of invasive aspergillosis
  • Pulmonary lesion in proximity to great vessels or pericardium;
  • Pericardial infection;
  • Invasion of chest wall from contiguous pulmonary lesion;
  • Aspergillus empyema;
  • Persistent hemoptysis from a single cavitary lesion;
  • Infection of skin and soft tissues;
  • Infected vascular catheters and prosthetic devices;
  • Endocarditis;
  • Osteomyelitis;
  • Sinusitis;
  • Cerebral lesions.

References

  1. ↑ http://www.cdc.gov/fungal/aspergillosis/treatment.html
  2. ↑ Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J, Kern W, Marr K, Ribaud P, Lortholary O, Sylvester R, Rubin R, Wingard J, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar P, Hodges M, Schlamm H, Troke P, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. (2002). "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis". N Engl J Med. 347 (6): 408–15. PMID 12167683. Unknown parameter |month= ignored (help)
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA; et al. (2008). "Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America". Clin Infect Dis. 46 (3): 327–60. doi:10.1086/525258. PMID 18177225.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G (2014). "Invasive fungal infections in the ICU: how to approach, how to treat". Molecules. 19 (1): 1085–119. doi:10.3390/molecules19011085. PMID 24445340.

Template:Mycoses


} Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Aspergillosis_medical_therapy&oldid=1126432"